CJ Bioscience continued to show sluggish performance in 2022 even after CJ Group, a Korean conglomerate, acquired the company.CJ Group acquired Chunlab, which specializes in microbiome treatment, in January last year and restarted its bio-business after renaming the company to CJ Bioscience.At that
Koreans in their 30s and 40s will likely be the first generation to age faster than their parents because they are exposed to an “accelerated aging environment,” an expert said.Professor Jung Hee-won of Geriatric Medicine at Asan Medical Center (AMC) in Seoul said so at a round-table meeting hosted
SK Bioscience said CEO Ahn Jae-yong presented global partnership strategies for overcoming the next pandemic by establishing regional vaccine hubs at the 2023 Riyadh Global Medical Biotechnology Summit in Riyadh, Saudi Arabia, on Wednesday.The Riyadh Summit is a national event where global bioindust
HK inno.N said it has signed an exclusive license agreement with Spain's mAbxience to market the latter's Prolia (ingredient: denosumab) biosimilar, a preventive treatment for osteoporosis and cancer-related skeletal complications, in Korea.Under the contract, HK inno.N will exclusively market two t
Celltrion said it had increased its stake in Iksuda Therapeutics, a U.K.-based antibody-drug conjugate (ADC) developer, to 47.05 percent through direct investment and Mirae Asset-Celltrion New Growth Fund 1.As a result, Celltrion and the new growth fund rose to become the largest shareholders of Iks
A team of researchers at the Korea Research Institute of Bioscience and Biotechnology (KRIBB) has developed a CRISPRi-based plasmid selection system by building a cascaded logic inverter to mimic antibiotics and thereby reduce antibiotic-resistance genes.Antibiotic screening is most widely used to s
With their biosimilars, Samsung Bioepis and Chong Kun Dang will soon compete to secure a larger ranibizumab market share for treating wet age-related macular degeneration in Korea. The wet age-related macular degeneration (wAMD) treatment market is expected to see fierce competition this year as Sam
Daewoong Bio is planning to enter the contract development and manufacturing organization (CDMO) business through large-scale investment.Daewoong Bio said Monday that it will invest 146 billion won ($117.9 million) to build a new biological drug plant in Hyangnam, Gyeonggi Province, where the compan
A research team at Yonsei University College of Medicine published a study, saying the delivery of antibody treatments like aducanumab can be improved 8.1 times with focused ultrasound (FUS) targetted to the blood-brain barrier (BBB) of mice.Alzheimer's is known to be associated with the accumulatio
SAN FRANCISCO, Calif. -- By Lee Han-soo/Korea Biomedical Review correspondent – Samsung Biologics unveiled its aspiration to become a top-tier global biopharmaceutical company by 2030 during the 2023 J.P. Morgan Healthcare Conference's Main Track on Wednesday. John Rim, CEO of the biotech unit of Sa
A team of researchers at the Ajou University School of Medicine conducted a study on inhaled corticosteroid (ICS)-formoterol treatments and found that they can effectively prevent the occurrence of serious asthmatic exacerbations.The study cohort included 743 adult asthma patients who received asthm
Researchers in Korea said they discovered a new immune checkpoint inhibitor called NgR1 which suppresses the activity of natural killer (NK) cells in cancer.Surgery, radiation therapy, and chemotherapy have been used as major treatments for cancer. However, many cancer patients suffer from physical
Ranking Chicken (랭킹닭), a seller of chicken breast products, issued a formal apology on its website on Tuesday for causing concern to customers due to a problem with the nutrition labeling of Bestik chicken breast sausages.The issue sparked concern after a Youtuber, Neoguri Dago, who produces content
Samsung Bioepis has obtained a domestic product license for high-concentration Humira (adalimumab) biosimilars. Competition for prescription with Celltrion, which released high-concentration formulations in Korea and with the original drug, is drawing the industry’s attention.According to the Minist
Daewoong Pharmaceutical said on Thursday that they signed a contract with Oncorus, a U.S. bioventure that develops next-generation RNA-based immunotherapies, for the joint development and commercialization of lipid nanoparticle (LNP) mRNA drugs.Through this contract, the two companies plan to develo
The CES 2023 tech trends session outlined how digital health technologies were transforming homes into a health hub and featured SK Biopharmaceuticals’ epilepsy wearables on Tuesday in Las Vegas, Nev., the U.S.The session was delivered by Steve Koenig, VP of Research at CTA, who highlighted global c
Kim Tae-han, chairman of the Samsung Biologics’ board of directors, is drawing attention because of his back-to-back sales of the company stocks.According to a public filing by Samsung Biologics, Chairman Kim sold 2,460 and 940 shares in the market last Wednesday and Thursday. As a result, his selli
Lotte Biologics said it has completed the acquisition of Bristol Myers Squibb (BMS) 's biopharmaceutical production plant in Syracuse, New York, the U.S., and has taken the first step toward entering the bio-industry.The company had previously signed a contract to acquire BMS' biopharmaceutical prod
Aprogen, which raised investors’ expectations by announcing acquiring a drug manufacturing facility in the U. S., has reversed the announcement and abandoned its acquisition.“In these times of global business slump, we thought the investment risk would increase sharply and decided not to push for th
Inventage Lab is inviting gossip in the market by releasing news material different from facts about its clinical trials of new drug candidates.On Monday, the company, a microfluidics-based drug developer, distributed a news release headlined, “Applying for phase 1 clinical trial in Australia for lo